At Kedalion,
we see a better way...

Kedalion Therapeutics is a clinical-stage, venture-funded ophthalmic drug company based in Menlo Park, CA. Kedalion's AcuStream technology delivers topical drugs to the eye in a precise and accurate manner that enables comparable efficacy with an 80% reduction in dose compared to standard drops, and a significantly improved side effect profile along with patient comfort and convenience following self-administration.

Management Team

Peter Noymer, Ph.D.

Peter Noymer, PhD

President & Chief Executive Officer

Close
Peter Noymer, Ph.D.

Peter Noymer, PhD

President & Chief Executive Officer

Peter Noymer has served as President and CEO of Kedalion Therapeutics since November 2017, bringing to the role more than 20 years of experience in research, development and commercialization of pharmaceutical products with novel delivery system technologies. Prior to joining Kedalion, Peter was COO at SteadyMed Therapeutics, a specialty pharmaceutical company focused on treating major unmet medical needs with its proprietary PatchPump™ technology. Earlier, Peter worked in the respiratory drug delivery space as VP of Product R&D at Alexza Pharmaceuticals where they obtained US and EU approval for Adasuve®, the first inhalable treatment for acute agitation, and in various management positions at Aradigm Corporation. Peter received MS and PhD degrees in engineering from MIT, and a BS degree in engineering with honors from Princeton University.

Ehud Ivri, MSc

Ehud Ivri, MSc

Chief Technology Officer & Co-Founder

Close
Ehud Ivri, MSc

Ehud Ivri, MSc

Chief Technology Officer & Co-Founder

Ehud Ivri is Kedalion’s CTO and Co-Founder. He is an electro-mechanical engineer specializing in microfluidics and piezoelectronics, and his work is focused mainly in the field of drug delivery and pharmaceuticals. Ehud holds over 40 patents related to medical devices and drug delivery systems. Ehud’s work in the medical device field began with his founding of Aerogen, now a leading producer of nebulizers for inhalation drug delivery based on his invention. More recently, Ehud developed a new micro-dispensing technology for the production of DNA micro-arrays that was licensed to BioDot Inc. in Irvine, California. Ehud holds a Master of Science degree in mechanical engineering from the Technion-Israel Institute of Technology.

Mark Murray

Mark Murray

Chief Financial Officer

Close
Mark Murray

Mark Murray

Chief Financial Officer

Mark has been a CFO in the life science sector for over 30 years, working with senior executives and their boards. His eye care experience includes the successful exits of OptiMedica and Oculeve. Mark spent over 20 years with Guidant Corporation, where he was part of the senior management team and in its $1 billion IPO thru its exit in 2006 for $27 billion (by Boston Scientific and Abbott Labs). He has helped raise over $1.6 billion in equity and over $500 million in debt for public and private companies. Mark is currently a partner at FLG Partners, LLC. He holds a BS in business administration (accounting) from San Francisco State University.

Reynaldo Quintana

Reynaldo Quintana

Vice President of Engineering

Close
Reynaldo Quintana

Reynaldo Quintana

Vice President of Engineering

Reynaldo Quintana has served as Kedalion’s VP of Engineering since August 2018. Prior to Kedalion, he was Senior Director of Global Engineering at Fontem Ventures, B.V., leading product development for next-generation platforms. He also led mechanical device development at Alexza Pharmaceuticals which obtained US and EU approval for Adasuve®, the first inhalable treatment for acute agitation. Reynaldo has also held management positions with leading companies such as NJOY, Inc., ZOLL Medical Corporation (formerly Revivant), Aerogen, and IDEO, and has served as an engineering and product development consultant to Sunovion Pharmaceuticals, Genentech and Elevation Pharmaceuticals. He is an inventor or co-inventor on 18 patents related to medical devices and drug delivery systems. Reynaldo received a B.S. in mechanical engineering from the University of Maryland College Park and a B.S. in physics from Frostburg State University, and an M.S. in biomedical engineering from The Catholic University of America.

Board of Directors

Mark Blumenkranz, M.D., MMS

Mark Blumenkranz, MD, MMS

Executive Chairman & Co-Founder

Close
Mark Blumenkranz, M.D., MMS

Mark Blumenkranz, MD, MMS

Executive Chairman & Co-Founder

Mark Blumenkranz is Kedalion’s Executive Chairman and Co-Founder, and also the Chairman and Managing Director of Lagunita Biosciences, a venture incubator that creates and grows early-stage companies to commercialize impactful translational science that addresses significant clinical needs. Dr. Blumenkranz is now the HJ Smead Professor Emeritus at the Byers Eye Institute and Department of Ophthalmology at Stanford University and served as departmental Chairman from 1997 to 2015. He played a leading role in the planning, fundraising and construction of the Institute which opened in 2010. Mark has a longstanding interest and expertise in university corporate technology transfer and early-stage biomedical companies and was a Founder and Director of Macusight, Peak Surgical, Optimedica Corporation, Adverum Biotechnologies, Oculeve, and Digisight Corporation (now Verana Heath). He has also served on the Boards of Directors of a number of other private and publicly traded ophthalmic drug and medical device companies including Oculex Pharmaceuticals, OIS, Midlabs, Presbia, and Beaver-Visitec (BVI Inc). He completed the Stanford Executive Program in the Graduate School of Business in 2004 and received his Undergraduate, Masters degree in biochemical pharmacology, and MD degrees from Brown University (AOA), where he is also a Fellow of the Corporation and immediate past Chair of the Medical School Committee.

Darius Kharabi

Darius Kharabi

Chief Operating Officer, Lagunita Biosciences

Close
Darius Kharabi

Darius Kharabi

Chief Operating Officer, Lagunita Biosciences

Darius Kharabi is COO of Lagunita Biosciences. Prior to Lagunita, Mr. Kharabi was the General Manager of EMBA Medical Ltd, an early stage endovascular device company, and an entrepreneur-in-residence with Intersect Partners, a medical device incubator. Earlier, he served as Vice President, Corporate Development and International Sales at OrthAlign Inc., a commercial stage orthopedic surgery navigation company, where his responsibilities included the launch of the KneeAlign® total knee arthroplasty navigation product line in North America, Europe, Asia and Australia. Prior to that, Darius was a Partner at VLP Law Group LLP and a biotechnology licensing attorney at Wilson, Sonsini Goodrich & Rosati PC. Mr. Kharabi received his B.S. in Biochemistry from Georgetown University and his J.D. and M.B.A. degrees from Stanford University.

Dana Mead

Dana Mead

Chief Executive Officer, Beaver-Visitec International

Close
Dana Mead

Dana Mead

Chief Executive Officer, Beaver-Visitec International

Dana Mead is President and CEO of Beaver-Visitec International (BVI) and brings over 30 years of operational and investor experience in medical devices. Prior to BVI, Dana was a Strategic Advisor and Partner in the Life Science Practice of Kleiner Perkins Caufield & Byers (KPCB), a leading venture capital firm, where he helped identify and grow early-stage healthcare companies. Prior to KPCB, he held a series of senior-level positions at Guidant Corp. Earlier in his career, Dana served in sales and marketing roles in the ophthalmic groups of Allergan and Johnson & Johnson. Mr. Mead has a Bachelor’s Degree from Lafayette College and a Masters of Business Administration (MBA) from the University of Southern California.

John Power

John Power

Chief Executive Officer, Aerogen

Close
John Power

John Power

Chief Executive Officer, Aerogen

A Serial Entrepreneur in a technology and innovation focused career spanning over 30 years, John has held executive level positions in R&D, Operations, Sales and General Management in both the SME and MNC environment. During this period he has been a founder or co-founder of several ‘Blue Ocean’ technology start-ups the last three of these in the life-science sector.

John has led Aerogen from start-up in 1997 through a US merger, subsequent NASDAQ IPO, acquisition and MBO in 2008. Today Aerogen is recognized as a pioneer in high performance nebulisation and a global leader in ICU ventilator / Hospital based aerosol drug delivery. Its award winning products are employed in over 75 countries throughout the world helping to provide life critical interventions from the emergency department through to the NICU. Aerogen’s proprietary technology permits proteins, peptides, suspensions and solutions to be nebulised paving the way for targeted drug delivery to the lung.

Since 2008 the company has grown revenues 30%+ year on year and in recognition of its export success Aerogen was awarded the prestigious European Business Award Ruban d’Honneur in 2011 and again in 2016, where John was also named the European Entrepreneur of the Year. Aerogen was named the Irish Exporter of the Year 2014. In 2013, 2015 & 2016 Aerogen received the highest award granted by the American Association of Respiratory Care, the Zenith Award, for ‘providing products and services that enable respiratory care physicians and therapists to achieve clinical excellence’. Also in 2013 Aerogen was voted Irish Med-Tech Company of the year.

A Chartered Engineer, John is recognized as a technology innovator and is credited with over a dozen commercialized International patents in products ranging from robotics to life-support ventilation. He holds an MBA from Oxford Brookes University and as an Adjunct Lecturer at National University of Ireland Galway (NUIG), he guest lectures on his core business interests of Innovation Strategies and Technology Entrepreneurship.

He is a founder faculty member of the NUIG Bio-Innovate program (run in conjunction with Stanford University Bio-Design), an incubator unit that promotes entrepreneurial start-up’s in medical technologies where he has actively mentored several early stage companies. In 2016 in recognition of his contribution to the development of the Irish Medical Device sector John was conferred with an Honorary Doctorate by the National University of Ireland Galway.

John is a senior member of the Board of the Irish Medical Device Association where he has represented Ireland as an Industry expert in the European Competitive Council in Brussels. He previously served as a Board member of The Irish Research Council for Science, Engineering and Technology.

John is a very active social entrepreneur in both his community where he has been chairman and long-term member of his Community Development Association and Internationally through Foundation Nepal and World Vision where he has led significant fundraising initiatives for irrigation / agricultural and local enterprise development.

Peter Noymer, Ph.D.

Peter Noymer, PhD

President & Chief Executive Officer

Close
Peter Noymer, Ph.D.

Peter Noymer, PhD

President & Chief Executive Officer

Peter Noymer has served as President and CEO of Kedalion Therapeutics since November 2017, bringing to the role more than 20 years of experience in research, development and commercialization of pharmaceutical products with novel delivery system technologies. Prior to joining Kedalion, Peter was COO at SteadyMed Therapeutics, a specialty pharmaceutical company focused on treating major unmet medical needs with its proprietary PatchPump™ technology. Earlier, Peter worked in the respiratory drug delivery space as VP of Product R&D at Alexza Pharmaceuticals where they obtained US and EU approval for Adasuve®, the first inhalable treatment for acute agitation, and in various management positions at Aradigm Corporation. Peter received MS and PhD degrees in engineering from MIT, and a BS degree in engineering with honors from Princeton University.

Scientific Advisory Board

William Culbertson, M.D.

William Culbertson, MD

Scientific Advisory Board

Close
William Culbertson, M.D.

William Culbertson, MD

Scientific Advisory Board

William Culbertson, M.D., is the Lou Higgins Chair of Ophthalmology and Professor of Ophthalmology at the University of Miami’s Bascom Palmer Eye Institute and is actively involved in clinical practice in cataracts, intraocular lenses, corneal diseases, and laser vision correction. He received his BA and MD degrees from Emory University in Atlanta, and did his residency in ophthalmology at Vanderbilt University Hospital in Nashville. He completed fellowships in corneal and external diseases at the Bascom Palmer Eye Institute in Miami and at the Francis I. Proctor Foundation for Research in Ophthalmology in San Francisco.

Richard Lewis, M.D.

Richard Lewis, MD

Scientific Advisory Board

Close
Richard Lewis, M.D.

Richard Lewis, MD

Scientific Advisory Board

Richard Lewis, M.D., is the former director of glaucoma at the University of California and is currently in clinical practice with Sacamento Eye Consultants in Sacramento, CA. Dr. Lewis is actively involved in clinical research in glaucoma therapy. Dr. Lewis is on the editorial board of the Journals of Cataract and Refractive Surgery, Glaucoma, and Glaucoma Today. Dr. Lewis attended the University of California, Berkeley as an undergraduate and received his doctorate in medicine from Northwestern University Medical School in Chicago. His professional training included an internship in internal medicine at Northwestern University Evanston Hospital; a residency at the Department of Ophthalmology at the University of California, Davis; and a fellowship in glaucoma at the University of Iowa Department of Ophthalmology. He has received the American Academy of Ophthalmology Honor and Senior Honor Awards for his contributions in teaching and leadership. He is a past President of the American Glaucoma Society and a past President of the American Society of Cataract and Refractive Surgeons.

Strategic Advisors

Marc Gleeson

Marketing

Judy Gordon, DVM

Clinical & Regulatory

David Myung, MD, PhD

Medical & R&D

Daniel Palanker, PhD

R&D

Doug Solomon, PhD

Product Design

Jeffrey Price, MME

Manufacturing

We see a better way.

Want more information on our AcuStream™ technology.

Contact us